(NASDAQ: IRD) Opus Genetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.06%.
Opus Genetics's earnings in 2026 is -$106,932,000.On average, 16 Wall Street analysts forecast IRD's earnings for 2026 to be -$45,923,363, with the lowest IRD earnings forecast at -$62,218,750, and the highest IRD earnings forecast at -$29,912,861. On average, 15 Wall Street analysts forecast IRD's earnings for 2027 to be -$48,755,928, with the lowest IRD earnings forecast at -$67,802,484, and the highest IRD earnings forecast at -$23,930,288.
In 2028, IRD is forecast to generate -$49,781,512 in earnings, with the lowest earnings forecast at -$71,790,865 and the highest earnings forecast at -$17,093,063.